Generic Firms Want Congress To Build On CARES Act To Prevent Critical Drug Shortages
Executive Summary
The association for manufacturers of generics and biologics calls for public sector investment in priority medicines.
You may also be interested in...
US FDA’s Machine Learning Analysis Suggests Where To Look For Manufacturing Site Quality Problems
XGBoost model sees site complexity contributes to quality risk, but misses device-related issues, says third FDA pharmaceutical quality report.
Continuous Manufacturing Centers Of Excellence Measure Resurfaces In US House
Stand-alone bill headed for Senate, where it fared poorly in coronavirus response legislative packages.
COVID-19 Funds Flow To Startup In Bid To Restore US Pharmaceutical Manufacturing
Trump administration infuses Phlow with potentially $800m-plus for fully integrated domestic manufacture of essential medicines for COVID-19 and other crises. Key figures in new approaches to securing drugs and experts on China helped frame the project’s approach.